X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4382) 4382
Dissertation (77) 77
Book Chapter (76) 76
Publication (32) 32
Conference Proceeding (29) 29
Journal / eJournal (1) 1
Magazine Article (1) 1
Paper (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2901) 2901
life sciences & biomedicine (2869) 2869
glp-1 (2672) 2672
humans (1765) 1765
animals (1344) 1344
endocrinology & metabolism (1260) 1260
type 2 diabetes (1233) 1233
male (1199) 1199
diabetes (1086) 1086
glucagon (931) 931
diabetes mellitus, type 2 - drug therapy (805) 805
insulin (798) 798
female (769) 769
glucose (674) 674
hypoglycemic agents - therapeutic use (566) 566
obesity (551) 551
pharmacology & pharmacy (538) 538
peptides (529) 529
middle aged (517) 517
glucagon-like peptide 1 (506) 506
liraglutide (493) 493
mice (458) 458
adult (447) 447
rats (447) 447
diabetes mellitus (434) 434
blood glucose - metabolism (430) 430
dextrose (427) 427
glucagon-like peptide 1 - metabolism (425) 425
internal medicine (382) 382
glucagon-like peptide-1 (375) 375
analysis (365) 365
insulin - metabolism (350) 350
medicine & public health (345) 345
digestive, oral, and skin physiology (335) 335
biochemistry & molecular biology (334) 334
glucagon-like peptide-1 receptor (333) 333
gip (330) 330
exenatide (321) 321
insulin secretion (318) 318
diabetes mellitus, type 2 - blood (313) 313
glp‐1 (311) 311
glp-1 receptor agonist (305) 305
hypoglycemic agents - pharmacology (293) 293
incretin (292) 292
aged (290) 290
blood glucose - drug effects (281) 281
glucagon-like peptide 1 - analogs & derivatives (281) 281
diabetes mellitus, type 2 - metabolism (277) 277
hypoglycemic agents - administration & dosage (272) 272
treatment outcome (270) 270
endocrine system (269) 269
insulin - blood (267) 267
glucose metabolism (263) 263
glucagon-like peptide 1 - blood (248) 248
insulin resistance (248) 248
diabetes therapy (247) 247
physiological aspects (247) 247
glp-1 receptor agonists (245) 245
hormones, hormone substitutes, and hormone antagonists (244) 244
body weight (233) 233
hypoglycemic agents (233) 233
type 2 diabetes mellitus (232) 232
glucagon-like peptide 1 - pharmacology (228) 228
care and treatment (216) 216
hypoglycemic agents - adverse effects (215) 215
peptides - pharmacology (210) 210
research (210) 210
glucagon-like peptide 1 - therapeutic use (203) 203
glucagon-like peptide-1 receptor - agonists (203) 203
health aspects (188) 188
review (188) 188
clinical trials (186) 186
mice, inbred c57bl (186) 186
drug therapy (185) 185
incretins (177) 177
surgery (176) 176
cell biology (174) 174
neurosciences (174) 174
physiology (171) 171
peptides - therapeutic use (169) 169
risk factors (169) 169
receptors, glucagon - metabolism (167) 167
dpp-4 inhibitors (164) 164
dipeptidyl-peptidase iv inhibitors - therapeutic use (163) 163
endocrinology (163) 163
receptors, glucagon - agonists (162) 162
exendin-4 (160) 160
glucose tolerance test (160) 160
neurosciences & neurology (160) 160
diabetes mellitus, type 2 - physiopathology (159) 159
dose-response relationship, drug (159) 159
medicine, research & experimental (159) 159
hypoglycemia (158) 158
research & experimental medicine (158) 158
rodents (158) 158
double-blind method (156) 156
diabetes mellitus, type 2 - complications (153) 153
general & internal medicine (153) 153
weight loss (153) 153
original (152) 152
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4050) 4050
Chinese (267) 267
French (93) 93
Japanese (89) 89
German (59) 59
Spanish (32) 32
Czech (13) 13
Portuguese (12) 12
Korean (10) 10
Polish (7) 7
Italian (6) 6
Russian (6) 6
Hungarian (5) 5
Persian (2) 2
Swedish (2) 2
Croatian (1) 1
Dutch (1) 1
Indonesian (1) 1
Norwegian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular metabolism (Germany), ISSN 2212-8778, 10/2015, Volume 4, Issue 10, pp. 718 - 731
Abstract Objective Although Glucagon-like peptide 1 is a key regulator of energy metabolism and food intake, the precise location of GLP-1 receptors and the... 
Endocrinology & Metabolism | Electrophysiology | GLP-1 | Preproglucagon | PPG | Channelrhodopsin | Glucagon-like peptide-1 receptor | Life Sciences & Biomedicine | Science & Technology
Journal Article
Medicina clínica, ISSN 0025-7753, 2014, Volume 143, pp. 8 - 11
Modulation of the incretin effect has opened up a new strategy in the treatment of diabetes mellitus type 2 (DM2). To date, this physiological mechanism has... 
Incretin | Inhibidor DPP-4 | Incretina | GLP-1 | Glucagon | Análogo receptor GLP-1 | GLP-1 analog | Glucagón | Gastric emptying | Vaciamiento gástrico | GIP | GLP-1 analog receptor | DPP-4 inhibitor | Análogo GLP-1 | Diabetes
Journal Article
Medicina clínica, ISSN 0025-7753, 2014, Volume 143, pp. 12 - 17
Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion... 
Postprandial effect | Agonistas del receptor de GLP-1 | GLP-1 | DPP-4 | Duration of effect | Exendin-4 | Efecto posprandial | Análogos del GLP-1 | Individualization of drug therapy | Duración de efecto | GLP-1 receptor agonists | Exendina-4 | Individualización terapéutica | GLP-1 analogs
Journal Article
Current diabetes reviews, ISSN 1573-3998, 01/2014, Volume 10, Issue 4, pp. 238 - 250
Journal Article
Current diabetes reviews, ISSN 1573-3998, 2013, Volume 9, Issue 2, pp. 161 - 193
Journal Article
Molecular Metabolism, ISSN 2212-8778, 2014, Volume 3, Issue 9, pp. 823 - 833
Abstract Background/objectives Fasting dyslipidemia is commonly observed in insulin resistant states and mechanistically linked to hepatic overproduction of... 
Endocrinology & Metabolism | Glucagon-like peptide-1 (GLP-1) | Incretin | Insulin resistance | Hepatic steatosis | Fasting dyslipidemia | Very low density lipoprotein (VLDL) | Life Sciences & Biomedicine | Science & Technology
Journal Article
Development of new incretin drugs: promising therapies, 12/2006
New agents are being added to the armamentarium of drugs used for the treatment of diabetes mellitus. Today, extensive research is being conducted on incretin... 
Diabetes mellitus, GLP-1, GIP, DPP-IV
Journal
Canadian Journal of Physiology and Pharmacology, ISSN 0008-4212, 2018, Volume 96, Issue 6, pp. 587 - 596
Nonalcoholic fatty liver disease (NAFLD) is often associated with obesity and type 2 diabetes. Coagonists of glucagon-like peptide-1 receptor (GLP-1R) and... 
coagonist of GLP-1 and glucagon receptors | NAFLD | coagoniste des récepteurs de GLP-1 et du glucagon | GLP-1 | inflammation | glucagon | SHNA | Inflammation | Glucagon | Coagonist of GLP-1 and glucagon receptors | Pharmacology & Pharmacy | Physiology | Life Sciences & Biomedicine | Science & Technology | Receptors, Glucagon - agonists | Non-alcoholic Fatty Liver Disease - pathology | Liver - pathology | Liver - metabolism | Male | Non-alcoholic Fatty Liver Disease - metabolism | Glucagon - pharmacology | Non-alcoholic Fatty Liver Disease - drug therapy | Peptides - pharmacology | Animals | Liver - drug effects | Glucagon-Like Peptide 1 - agonists | Venoms - therapeutic use | Glucagon - therapeutic use | Mice | Venoms - pharmacology | Peptides - therapeutic use | Care and treatment | Cell receptors | Usage | Fatty liver | Physiological aspects | Peptide hormones | Health aspects | Agonists (Biochemistry) | Animal models | Collagen (type I) | Peptides | Carbon tetrachloride | Amino acids | Tissue inhibitor of metalloproteinase 1 | High fat diet | Receptors | Reduction | Rodents | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Obesity | Liver diseases | Diabetes mellitus | Pharmacology | Tumor necrosis factor-α | CCL4 protein | Gelatinase B | Feeding | Steatosis | Choline | Fibrosis | Diabetes | Monocyte chemoattractant protein 1 | Index Medicus
Journal Article
Diabetes & Metabolism, ISSN 1262-3636, 2016, Volume 42, pp. A43 - A43
Introduction La survenue précoce d'EI GI transitoires est caractéristique des AR GLP-1. Type/fréquence de ces événements peuvent varier selon durée d'action de... 
Internal Medicine | Endocrinology & Metabolism | Agoniste du récepteur au Glp-1 | Diabète de type 2 | GLP-1
Journal Article